PledPharma AB | Innovative, unique and integrated competence in pharmaceutical drug development with focus on improving treatments for severe diseases with substantial unmet medical need where alternative treatments does not exist

PledPharma has an innovative, unique and integrated competence in pharmaceutical drug development with focus on improving treatments for severe diseases with substantial unmet medical need where alternative treatments doesn’t exist.

PledPharma in the media

Pipeline

Redeye interview with the CEO, December

Press Releases

Regulatory

January 23, 2020

PledPharma provides update on the clinical POLAR program, clinical hold in the US

January 8, 2020

PledPharma to initiate one pivotal Phase II/III study with Aladote® for marketing authorisation application in both US and EU

December 16, 2019

Global phase III study POLAR-A fully recruited

Latest Report

October 23, 2019

Latest interim report

March 29, 2019

Annual report 2018

Latest presentation

January 23, 2020

Telephone conference - update on the clinical POLAR program, clinical hold in the US

Calendar and upcoming reports

February 18, 2020

Year end report

March 3-4, 2020

Carnegie Nordic Healthcare Seminar

April 22, 2020

Interim report first quarter 2020

April 23, 2020

Annual General Meeting

August 20, 2020

Interim report second quarter 2020

November 4, 2020

Interim report third quarter 2020

Contact us

Address: Grev Turegatan 11 C, 114 46 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@pledpharma.com